CA2396040A1 - Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations - Google Patents

Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations Download PDF

Info

Publication number
CA2396040A1
CA2396040A1 CA002396040A CA2396040A CA2396040A1 CA 2396040 A1 CA2396040 A1 CA 2396040A1 CA 002396040 A CA002396040 A CA 002396040A CA 2396040 A CA2396040 A CA 2396040A CA 2396040 A1 CA2396040 A1 CA 2396040A1
Authority
CA
Canada
Prior art keywords
polypeptide
nucleic acid
ceg
ligand
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396040A
Other languages
English (en)
Inventor
Thomas J. Dougherty
Michael J. Pucci
Brian A. Dougherty
Daniel B. Davison
Robert E. Bruccoleri
Jane A. Thanassi
Bennett T. Ii Farmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396040A1 publication Critical patent/CA2396040A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux gènes bactériens et leurs polypeptides codés qui sont essentiels pour la viabilité des cellules bactériennes, et leur utilisation.
CA002396040A 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations Abandoned CA2396040A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17408999P 1999-12-30 1999-12-30
US60/174,089 1999-12-30
PCT/US2000/035604 WO2001049721A2 (fr) 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2396040A1 true CA2396040A1 (fr) 2001-07-12

Family

ID=22634783

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396040A Abandoned CA2396040A1 (fr) 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1261630A2 (fr)
AU (1) AU4300601A (fr)
CA (1) CA2396040A1 (fr)
IL (1) IL149472A0 (fr)
WO (1) WO2001049721A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
FR2807764B1 (fr) 2000-04-18 2004-09-10 Agronomique Inst Nat Rech Mutants de bacteries lactiques surproducteurs d'exopolysaccharides
US6830898B2 (en) 2000-08-24 2004-12-14 Omnigene Bioproducts, Inc. Microorganisms and assays for the identification of antibiotics
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
US7056697B2 (en) 2000-10-06 2006-06-06 Affinium Pharmaceuticals, Inc. FabK variant
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US7033795B2 (en) 2000-10-06 2006-04-25 Affinium Pharmaceuticals, Inc. FabK variant
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2287315A1 (fr) 2003-03-04 2011-02-23 Intercell AG Antigènes pyogènes streptococcus
WO2004092209A2 (fr) * 2003-04-15 2004-10-28 Intercell Ag Antigenes s-pneumoniae
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AU2008287239A1 (en) * 2007-05-22 2009-02-19 Wisconsin Alumni Research Foundation Anti-bacterial drug targeting of genome maintenance interfaces

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6909098A (en) * 1996-10-31 1998-05-22 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
KR20010033721A (ko) * 1997-12-31 2001-04-25 밀레니엄 파머슈티컬스 인코퍼레이티드 필수 세균 유전자 및 이의 용도
US6268177B1 (en) * 1998-09-22 2001-07-31 Smithkline Beecham Corporation Isolated nucleic acid encoding nucleotide pyrophosphorylase

Also Published As

Publication number Publication date
AU4300601A (en) 2001-07-16
IL149472A0 (en) 2002-11-10
WO2001049721A3 (fr) 2002-09-12
WO2001049721A2 (fr) 2001-07-12
EP1261630A2 (fr) 2002-12-04

Similar Documents

Publication Publication Date Title
CA2396040A1 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
Bliss et al. Coating the surface: a model for expression of capsular polysialic acid in Escherichia coli K1
Glaser et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease
US8241642B2 (en) Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
Saurin et al. Sequence relationships between integral inner membrane proteins of binding protein‐dependent transport systems: Evolution by recurrent gene duplications
US20070134729A1 (en) Novel antibacterial agents
Lewinson et al. Promiscuity in multidrug recognition and transport: the bacterial MFS Mdr transporters
US20060241185A1 (en) Antibiotics targeting MreB
WO2005074986A2 (fr) Especes bioactive capables d'interferer avec un complexe toxine-antitoxine microbien et procedes d'evaluation et d'utilisation de ladite espece bioactive
CA2295376A1 (fr) Procedes d'identification d'agents anti-bacteriens et substances connexes
US20090111737A1 (en) Novel antibacterial agents
Moore et al. Divergent total synthesis and characterization of maxamycins
US7001924B2 (en) Inhibitors of RNase P proteins as antibacterial compounds
WO1999045136A1 (fr) Procedes d'analyse d'inhibiteurs de secretion de type iii
EP1461353A2 (fr) Cadres de lecture ouverts (orf) de la bacterie alloiococcus otitidis codant des polypeptides antigeniques, compositions imunogenes, et leurs utilisations
Kaufman et al. The toxin‐coregulated pilus: biogenesis and function
WO2001085773A2 (fr) Interactions luxo-sigma54 et applications
WO2003104391A2 (fr) Cibles antibacterienne de l'alloiococcus otitidis
US20050100899A1 (en) Screening assays
Tidten Structural and mutational characterisation of Shigella Pathogenicity Factors
Rocaboy Structural and biochemical study of the proteins AmiC, NlpD and FtsW involved in the bacterial cell division
Achila Molecular basis of pneumococcal adherence and complement evasion: Structural and biochemical studies of pneumococcal virulence factor, CbpA
Das Qsar analysis, docking & molecular dynamics simulation of several antimicrobial compounds and receptors
Bhaskaran Structural and Functional Characterization of B. Anthracis Udp-Glcnac 2-Epimerase and Salmonella Secreted Effector I
JP2005503831A (ja) 抗微生物方法および材料

Legal Events

Date Code Title Description
FZDE Discontinued